Cargando…

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)

Registry data are important for monitoring the impact of new therapies on treatment algorithms and outcomes, and for guiding clinical decision making in multiple myeloma (MM). This observational study analyzed real-world data from patients in the Population-based HAematological Registry for Observat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verelst, Silvia G.R., Blommestein, Hedwig M., De Groot, Saskia, Gonzalez-McQuire, Sebastian, DeCosta, Lucy, de Raad, Johan B., Uyl-de Groot, Carin A., Sonneveld, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746001/ https://www.ncbi.nlm.nih.gov/pubmed/31723779 http://dx.doi.org/10.1097/HS9.0000000000000045

Ejemplares similares

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands
por: Chen, Yi Hsuan, et al.
Publicado: (2023)

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
por: van Beurden-Tan, Chrissy H. Y., et al.
Publicado: (2022)

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting
por: Bouwmeester, Walter, et al.
Publicado: (2019)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review
por: Hájek, Roman, et al.
Publicado: (2020)

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
por: De Groot, S., et al.
Publicado: (2016)

Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
por: Klein, Philip, et al.
Publicado: (2022)

PHAROS—PHysical Assistant RObot System
por: Costa, Angelo, et al.
Publicado: (2018)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
por: Uyl‐de Groot, Carin A., et al.
Publicado: (2020)

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
por: Bennink, Christine, et al.
Publicado: (2023)

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
por: Campioni, M., et al.
Publicado: (2019)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
por: Ciani, Oriana, et al.
Publicado: (2021)

Pharos 2023: an integrated resource for the understudied human proteome
por: Kelleher, Keith J, et al.
Publicado: (2022)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
por: Heine, Renaud, et al.
Publicado: (2021)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Pharos: Collating protein information to shed light on the druggable genome
por: Nguyen, Dac-Trung, et al.
Publicado: (2017)

TCRD and Pharos 2021: mining the human proteome for disease biology
por: Sheils, Timothy K, et al.
Publicado: (2020)

Correction to ‘Pharos 2023: An integrated resource for the understudied human proteome’
Publicado: (2023)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
por: van der Gronde, Toon, et al.
Publicado: (2017)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence
por: Bosch, Dianne, et al.
Publicado: (2023)

PHAROS 2.0—A PHysical Assistant RObot System Improved
por: Martinez-Martin, Ester, et al.
Publicado: (2019)

Onderdiagnostiek bij kanker door de COVID-19-crisis naar diagnose, leeftijd en provincie: Een cruciale rol voor eerstelijnszorgverleners
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m8kank26sm6oefr0lrl8fpq7eg